Image source: Getty Images.
Embattled drugmaker Valeant Pharmaceuticals (NYSE: VRX) and its management team have had so many miscues since the summer of 2015 that Wall Street and investors have probably lost count.
Image source: Getty Images.
Embattled drugmaker Valeant Pharmaceuticals (NYSE: VRX) and its management team have had so many miscues since the summer of 2015 that Wall Street and investors have probably lost count.